BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32952995)

  • 1. Indole compounds with
    Li J; Ji J; Xu R; Li Z
    Medchemcomm; 2019 Nov; 10(11):1935-1947. PubMed ID: 32952995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives.
    Götz MR; Collado JA; Fernández-Ruiz J; Fiebich BL; García-Toscano L; Gómez-Cañas M; Koch O; Leha A; Muñoz E; Navarrete C; Pazos MR; Holzgrabe U
    Front Pharmacol; 2019; 10():1284. PubMed ID: 31824305
    [No Abstract]   [Full Text] [Related]  

  • 3. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
    Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
    Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cannabinoid CB
    Li AL; Carey LM; Mackie K; Hohmann AG
    J Pharmacol Exp Ther; 2017 Aug; 362(2):296-305. PubMed ID: 28592614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists.
    Dhopeshwarkar A; Murataeva N; Makriyannis A; Straiker A; Mackie K
    J Pharmacol Exp Ther; 2017 Feb; 360(2):300-311. PubMed ID: 27927913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Subtype Selective Cannabinoid CB
    Tang Y; Wolk B; Nolan R; Scott CE; Kendall DA
    Pharmaceuticals (Basel); 2021 Apr; 14(4):. PubMed ID: 33921589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-activity relationships of thiazole and benzothiazole derivatives as selective cannabinoid CB2 agonists with in vivo anti-inflammatory properties.
    Ghonim AE; Ligresti A; Rabbito A; Mahmoud AM; Di Marzo V; Osman NA; Abadi AH
    Eur J Med Chem; 2019 Oct; 180():154-170. PubMed ID: 31302448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The exogenous administration of CB2 specific agonist, GW405833, inhibits inflammation by reducing cytokine production and oxidative stress.
    Parlar A; Arslan SO; Doğan MF; Çam SA; Yalçin A; Elibol E; Özer MK; Üçkardeş F; Kara H
    Exp Ther Med; 2018 Dec; 16(6):4900-4908. PubMed ID: 30542446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile.
    Gómez-Cañas M; Morales P; García-Toscano L; Navarrete C; Muñoz E; Jagerovic N; Fernández-Ruiz J; García-Arencibia M; Pazos MR
    Pharmacol Res; 2016 Aug; 110():205-215. PubMed ID: 27013280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality.
    Osman NA; Ligresti A; Klein CD; Allarà M; Rabbito A; Di Marzo V; Abouzid KA; Abadi AH
    Eur J Med Chem; 2016 Oct; 122():619-634. PubMed ID: 27448919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMP-7 inhibits chronic inflammatory and neuropathic pain via block of Cav3.2 T-type calcium channels and activation of CB2 receptors.
    Berger ND; Gadotti VM; Petrov RR; Chapman K; Diaz P; Zamponi GW
    Mol Pain; 2014 Dec; 10():77. PubMed ID: 25481027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.
    Yrjölä S; Sarparanta M; Airaksinen AJ; Hytti M; Kauppinen A; Pasonen-Seppänen S; Adinolfi B; Nieri P; Manera C; Keinänen O; Poso A; Nevalainen TJ; Parkkari T
    Eur J Pharm Sci; 2015 Jan; 67():85-96. PubMed ID: 25447744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to develop selective CB
    Moir M; Lane S; Lai F; Connor M; Hibbs DE; Kassiou M
    Eur J Med Chem; 2019 Oct; 180():291-309. PubMed ID: 31319265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of selective cannabinoid CB(1) and CB(2) receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis.
    Tambaro S; Casu MA; Mastinu A; Lazzari P
    Eur J Pharmacol; 2014 Apr; 729():67-74. PubMed ID: 24561047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.
    Manley PJ; Zartman A; Paone DV; Burgey CS; Henze DA; Della Penna K; Desai R; Leitl MD; Lemaire W; White RB; Yeh S; Urban MO; Kane SA; Hartman GD; Bilodeau MT; Trotter BW
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2359-64. PubMed ID: 21420857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigations on the 4-quinolone-3-carboxylic acid motif. 2. Synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo.
    Pasquini S; Botta L; Semeraro T; Mugnaini C; Ligresti A; Palazzo E; Maione S; Di Marzo V; Corelli F
    J Med Chem; 2008 Aug; 51(16):5075-84. PubMed ID: 18680276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs.
    Reggio PH; Wang T; Brown AE; Fleming DN; Seltzman HH; Griffin G; Pertwee RG; Compton DR; Abood ME; Martin BR
    J Med Chem; 1997 Sep; 40(20):3312-8. PubMed ID: 9379452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
    Cheng Y; Albrecht BK; Brown J; Buchanan JL; Buckner WH; DiMauro EF; Emkey R; Fremeau RT; Harmange JC; Hoffman BJ; Huang L; Huang M; Lee JH; Lin FF; Martin MW; Nguyen HQ; Patel VF; Tomlinson SA; White RD; Xia X; Hitchcock SA
    J Med Chem; 2008 Aug; 51(16):5019-34. PubMed ID: 18680277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, Biodistribution and
    Ahamed M; van Veghel D; Ullmer C; Van Laere K; Verbruggen A; Bormans GM
    Front Neurosci; 2016; 10():431. PubMed ID: 27713686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties.
    Deiana V; Gómez-Cañas M; Pazos MR; Fernández-Ruiz J; Asproni B; Cichero E; Fossa P; Muñoz E; Deligia F; Murineddu G; García-Arencibia M; Pinna GA
    Eur J Med Chem; 2016 Apr; 112():66-80. PubMed ID: 26890113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.